Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-415S1 in Advanced Malignant Solid Tumors
NCT05886374Phase 1Recruiting
- Sponsor
- HUTCHMED
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HMPL-415S1 in advanced malignant solid tumor, sponsored by HUTCHMED. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
HMPL-415S1
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT05886374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886374.